Skip to content
Unrated Drug recall · FDA · Published July 7, 2021

Aurobindo Pharma Sulfamethoxazole-Trimethoprim Tablets Recall: Metal Contamination Risk

Aurobindo Pharma recalls 500-tablet sulfamethoxazole-trimethoprim (800mg/160mg) prescription medication due to potential metal contamination. This recall affects specific batches made in India with NDC 65862-420-05.

🇺🇸 FDA recall #D-0719-2021DrugAurobindo Pharma ›
Take action

Contact the company

Recalling firmAurobindo Pharma USA Inc.279 Princeton Hightstown Rd · East Windsor, NJ 08520-1401
✎ GovInfoNow plain-language explainer

Aurobindo Pharma is recalling prescription sulfamethoxazole-trimethoprim tablets that may contain metal contamination. This could pose a risk to users, though the exact danger level isn't specified in the recall notice. Read more at govinfonow.com/recall/36099-aurobindo-pharma-sulfamethoxazole-trimethoprim-tablets-recall-metal-contamination-risk.

Source Summary by GovInfoNow · govinfonow.com/recall/36099-aurobindo-pharma-sulfamethoxazole-trimethoprim-tablets-recall-metal-contamination-risk · Updated August 18, 2026 · FDA enforcement record: FDA #D-0719-2021

Cite this page

“Aurobindo Pharma Sulfamethoxazole-Trimethoprim Tablets Recall: Metal Contamination Risk.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/36099-aurobindo-pharma-sulfamethoxazole-trimethoprim-tablets-recall-metal-contamination-risk. Based on FDA recall #D-0719-2021 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0719-2021%22&limit=1).

Aurobindo Pharma USA Inc. recalled Sulfamethoxazole and Trimethoprim Tablets, USP due to potential metal contamination, the FDA announced on July 7, 2021. The voluntary Class II recall affects 3,800 bottles distributed nationwide.

How to tell if you have it

  • Brand: Aurobindo Pharma
  • Product: Sulfamethoxazole and Trimethoprim Tablets, USP, 800mg/160mg Double Strength
  • Quantity: 500 Tablets per bottle
  • NDC: 65862-420-05
  • Lot codes: SP1D19082AA3 and SP1D19085AA3
  • Expiration date: 08/2022
  • Distribution: Nationwide

The hazard

The recall cites the presence of a foreign substance, specifically potential metal contamination. The FDA classified this as a Class II recall.

Context

GovInfoNow's records show Aurobindo Pharma USA Inc. has issued 32 other recalls since April 9, 2013. Recent brand recalls include Dicyclomine Capsules recalled on July 23, 2026, for empty capsules and Acetaminophen Tablets recalled on May 22, 2025, due to discoloration risk. Other recent recalls of similar products include Guardian Drug Goodsense Ultra Strength Antacid Tablets (May 28, 2026) and Merck Noxafil Powdermix (Dec. 12, 2025).

How to tell if you have this one

Check for the NDC code 65862-420-05 on the packaging. Look for batch numbers SP1D19082AA3 or SP1D19085AA3. These tablets were made in India and expire in August 2022.

  • Brand
    Aurobindo Pharma
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Product Details

    Look for the NDC code 65862-420-05 and batch numbers SP1D19082AA3 or SP1D19085AA3 on the packaging.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 2.3 years after the firm started it.

1. Firm started the recall: Jul 7, 202112. FDA classified it Class II: Aug 10, 202123. Published in FDA’s Enforcement Report: Aug 18, 202134. FDA terminated the recall: Oct 18, 2023420212023
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Other Aurobindo Pharma recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0719-2021 (July 7, 2021) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0719-2021 to see it in context.
  • Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA